Literature DB >> 16774739

Anti-fibrogenic function of angiotensin II type 2 receptor in CCl4-induced liver fibrosis.

Yoshitaka Nabeshima1, Susumu Tazuma, Keishi Kanno, Hideyuki Hyogo, Masaru Iwai, Masatsugu Horiuchi, Kazuaki Chayama.   

Abstract

The renin-angiotensin system (RAS) contributes to fibrogenesis in a variety of organs. We recently showed that a lack of angiotensin (Ang) II type 1 (AT1) receptor activity reduces liver fibrosis. In this study, we investigated whether the Ang II type 2 (AT2) receptor is implicated in the development of liver fibrosis. A comparison was made between AT2-receptor knockout (AT2KO) and wild type (WT) mice after 4 weeks of treatment with carbon tetrachloride (CCl4). Fibrosis was assessed by Azan-Mallory staining and hepatic hydroxyproline (HP) content. The expression of fibrogenic mRNA was measured by real-time quantitative reverse-transcription polymerase chain reaction (PCR). Liver fibrosis evaluated by regular histological analyses and immunohistochemical alpha-SMA staining was observed in both groups of mice. The extent of fibrosis was greatest in the AT2KO mice. Fibrosis was associated with increases in hepatic HP content and mRNA expression for TGF-beta1 and alpha-SMA, as well as an increase in hepatic TBARS. These findings suggest that CCl4 induces oxidative stress which leads to activation of hepatic stellate cells (HSCs). These changes were considerably more pronounced in the AT2KO mice than the WT mice. Taken together, we conclude that AT2 signal has anti-fibrogenic and/or cytoprotective effects on oxidative stress-induced liver fibrosis. We therefore suggest that RAS-associated liver fibrogenesis may be determined by the balance between AT1 and AT2 signals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16774739     DOI: 10.1016/j.bbrc.2006.05.183

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

Review 1.  Current and future anti-fibrotic therapies for chronic liver disease.

Authors:  Don C Rockey
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

2.  The expression of ETAR in liver cirrhosis and liver cancer.

Authors:  Juhong Deng; Yu Huang; Ran Tao; Xiangxue Fan; Hongyue Zhang; Hongyan Kong; Qiqing Song; Jiaquan Huang
Journal:  Cancer Biol Ther       Date:  2017-08-16       Impact factor: 4.742

3.  Matrix metalloproteinase Mmp-1a is dispensable for normal growth and fertility in mice and promotes lung cancer progression by modulating inflammatory responses.

Authors:  Miriam Fanjul-Fernández; Alicia R Folgueras; Antonio Fueyo; Milagros Balbín; María F Suárez; M Soledad Fernández-García; Steven D Shapiro; José M P Freije; Carlos López-Otín
Journal:  J Biol Chem       Date:  2013-04-02       Impact factor: 5.157

Review 4.  Animal models for the study of liver fibrosis: new insights from knockout mouse models.

Authors:  Hiromitsu Hayashi; Takao Sakai
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-02-24       Impact factor: 4.052

5.  Angiotensin II induces endothelin-1 expression in human hepatic stellate cells.

Authors:  Chao He; Xiongying Miao; Jiequn Li; Haizhi Qi
Journal:  Dig Dis Sci       Date:  2013-04-27       Impact factor: 3.199

6.  Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis.

Authors:  E Bruce; V Shenoy; A Rathinasabapathy; A Espejo; A Horowitz; A Oswalt; J Francis; A Nair; T Unger; M K Raizada; U M Steckelings; C Sumners; M J Katovich
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

Review 7.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

Review 8.  Renin-angiotensin system in the pathogenesis of liver fibrosis.

Authors:  Regina Maria Pereira; Robson Augusto Souza dos Santos; Filipi Leles da Costa Dias; Mauro Martins Teixeira; Ana Cristina Simões e Silva
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

9.  Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment.

Authors:  Paschalis Paschos; Konstantinos Tziomalos
Journal:  World J Hepatol       Date:  2012-12-27

10.  Agaricus blazei Murill as an efficient hepatoprotective and antioxidant agent against CCl4-induced liver injury in rats.

Authors:  Abeer M Al-Dbass; Sooad K Al-Daihan; Ramesa Shafi Bhat
Journal:  Saudi J Biol Sci       Date:  2012-04-01       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.